Don't be too quick to jump on this biotech bandwagon.BioAge Labs (BIOA +1.02%) is a small drugmaker whose shares have caught fire this year. The company has made clinical progress in the hottest therapeutic area in the industry right now: Weight management. BioAge Labs' shares are up by 122% year to date.Even after recent developments, however, BioAge Labs' shares remain unattractive for investors focused on the long term. It'd be best to stay far away from the stock. Here are two reasons why. 1. Not even a ...